Contraception
Volume 73, Issue 5 , Pages 470-487 , May 2006

Progestogen-only contraception and bone mineral density: a systematic review

Received 14 December 2005 ,Revised 28 December 2005 ,Accepted 28 December 2005.

References 

  1. Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestogen-only contraceptives and bone mineral density. BJOG. 2001;108:1214–1221
  2. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ. 1991;303:13–16
  3. Merki-Feld GS, Neff M, Keller PJ. A prospective study on the effects of depot medroxyprogesterone acetate on trabecular and cortical bone after attainment of peak bone mass. BJOG. 2000;107:863–869
  4. Berenson AB, Radecki CM, Grady JJ, Rickert VI, Thomas A. A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol. 2001;98:576–582
  5. World Health Organization . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser. 1994;843:1–290
  6. Lappe JM, Stegman MR, Recker RR. The impact of lifestyle factors on stress fractures in female Army recruits. Osteoporos Int. 2001;12:35–42
  7. Ott SM, Scholes D, LaCroix AZ, Ichikawa LE, Yoshida CK, Barlow WE. Effects of contraceptive use on bone biochemical markers in young women. J Clin Endocrinol Metab. 2001;86:179–185
  8. Scholes D, LaCroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol. 1999;93:233–238
  9. Paiva LC, Pinto-Neto AM, Faundes A. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception. 1998;58:351–355
  10. Wanichsetakul P, Kamudhamas A, Watanaruangkovit P, Siripakarn Y, Visutakul P. Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception. 2002;65:407–410
  11. Gbolade B, Ellis S, Murby B, Randall S, Kirkman R. Bone density in long term users of depot medroxyprogesterone acetate. BJOG. 1998;105:790–794
  12. Cundy T, Cornish J, Roberts H, Elder H, Reid IR. Spinal bone density in women using depot medroxyprogesterone acetate contraception. Obstet Gynecol. 1998;92:569–573
  13. Tharnprisarn W, Taneepanichskul S. Bone mineral density in adolescent and young Thai girls receiving oral contraceptives compared with depot medroxyprogesterone acetate: a cross-sectional study in young Thai women. Contraception. 2002;66:101–103
  14. Perrotti M, Bahamondes L, Petta C, Castro S. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate. Fertil Steril. 2001;76:469–473
  15. Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K. Bone mineral density during long-term treatment with Norplant implants and depot medroxyprogesterone acetate. A cross-sectional study of Thai women. Contraception. 1997;56:153–155
  16. Taneepanichskul S, Intaraprasert S, Theppisai U, Chaturachinda K. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors. Contraception. 1997;56:1–3
  17. Bahamondes L, Perrotti M, Castro S, Faundes D, Petta C, Bedone A. Forearm bone density in users of Depo-Provera as a contraceptive method. Fertil Steril. 1999;71:849–852
  18. Petitti DB, Piaggio G, Mehta S, Cravioto MC, Meirik O. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol. 2000;95:736–744
  19. Virutamasen P, Wangsuphachart S, Reinprayoon D, Kriengsinyot R, Leepipatpaiboon S, Gua C. Trabecular bone in long-term depot-medroxyprogesterone acetate users. Asia Oceania J Obstet Gynaecol. 1994;20:269–274
  20. Tang OS, Tang G, Yip P, Li B, Fan S. Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception. 1999;59:25–29
  21. Beksinska ME, Smit JA, Kleinschmidt I, Farley TMM, Mbatha F. Bone mineral density in women aged 40–49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. Contraception. 2005;71:170–175
  22. Cundy T, Cornish J, Evans MC, Roberts H, Reid IR. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ. 1994;308:247–248
  23. Naessen T, Olsson SE, Gudmundson J. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception. 1995;52:35–39
  24. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 2002;13:581–587
  25. Berenson AB, Breitkopf CR, Grady JJ, Rickert VI, Thomas A. Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol. 2004;103:899–906
  26. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2004;82:1580–1586
  27. Cundy T, Ames R, Horne A, et al. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab. 2003;88:78–81
  28. Merki-Feld GS, Neff M, Keller PJ. A 2-year prospective study on the effects of depot medroxyprogesterone acetate on bone mass-response to estrogen and calcium therapy in individual users. Contraception. 2003;67:79–86
  29. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception. 2004;69:99–104
  30. Busen NH, Britt RB, Rianon N. Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health. 2003;32:257–259
  31. Cromer BA, Blair JM, Mahan JD, Zibners L, Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 1996;129:671–676
  32. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2004;17:17–21
  33. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. 2004;35:434–441
  34. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159:139–144
  35. Cromer BA, Lazebnik R, Rome E, et al. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol. 2005;192:42–47
  36. Tang OS, Tang G, Yip PS, Li B. Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: a longitudinal cohort study. Contraception. 2000;62:161–164
  37. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol. 1998;49:615–618
  38. Cundy T, Cornish J, Roberts H, Reid IR. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol. 2002;186:978–983
  39. Intaraprasert S, Taneepanichskul S, Theppisai U, Chaturachinda K. Bone density in women receiving Norplant implants for contraception. J Med Assoc Thai. 1997;80:738–741
  40. Di X, Li Y, Zhang C, Jiang J, Gu S. Effects of levonorgestrel-releasing subdermal contraceptive implants on bone density and bone metabolism. Contraception. 1999;60:161–166
  41. Diaz S, Reyes MV, Zepeda A, et al. Norplant® implants and progesterone vaginal rings do not affect maternal bone turnover and density during lactation and after weaning. Hum Reprod. 1999;14:2499–2505
  42. Vanderjagt DJ, Sagay AS, Imade GE, Farmer SE, Glew RH. Effect of Norplant contraceptive on the bones of Nigerian women as assessed by quantitative ultrasound and serum markers of bone turnover. Contraception. 2005;72:212–216
  43. Beerthuizen R, van Beek A, Massai R, Makarainen L, Hout J, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod. 2000;15:118–122
  44. Caird LE, Reid-Thomas V, Hannan WJ, Gow S, Glasier AF. Oral progestogen-only contraception may protect against loss of bone mass in breast-feeding women. Clin Endocrinol (Oxf). 1994;41:739–745
  45. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol. 2005;105:1114–1118
  46. Cefalu CA. Is bone mineral density predictive of fracture risk reduction?. Curr Med Res Opin. 2004;20:341–349
  47. Schonau E. The peak bone mass concept: is it still relevant?. Pediatr Nephrol. 2004;19:825–831
  48. Eisman J. Relevance of pregnancy and lactation to osteoporosis?. Lancet. 1998;352:504–505
  49. Karlsson C, Obrant KJ, Karlsson M. Pregnancy and lactation confer reversible bone loss in humans. Osteoporos Int. 2001;12:828–834
  50. Ensom MH, Liu PY, Stephenson MD. Effect of pregnancy on bone mineral density in healthy women. Obstet Gynecol Surv. 2002;57:99–111
  51. Chantry CJ, Auinger P, Byrd RS. Lactation among adolescent mothers and subsequent bone mineral density. Arch Pediatr Adolesc Med. 2004;158:650–656

PII: S0010-7824(06)00005-9

doi: 10.1016/j.contraception.2005.12.010

Contraception
Volume 73, Issue 5 , Pages 470-487 , May 2006

Article Tools

* Image Usage & Resolution